TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04065815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~* Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Description: HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 2 training sessions per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined HIIT and Resistance Training (Combi)
Description: HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 1 training session per week~Resistance Training:~* five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 1 training session per week
Study: NCT01557127

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
Study: NCT00717132

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based behavior modification
Description: Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
Study: NCT04165447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack labeling strategy
Description: We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack labeling strategy
Description: We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
Study: NCT00249912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and rosuvastatin
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study: NCT03851705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium for injection
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium for injection
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Study: NCT00249912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and rosuvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study: NCT03851705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% sodium chloride in water for injection)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sterile normal saline (0.9% sodium chloride in water for injection)
Study: NCT01486732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Infusion
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
Study: NCT00868972

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous renal stenting intervention
Description: Percutaneous renal stenting intervention
Study: NCT01486732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Umbilical Cord Blood
Description: Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
Study: NCT00692341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
Study: NCT00868972

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous renal stenting intervention
Description: Percutaneous renal stenting intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distal embolic protection
Description: Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
Study: NCT02346903

Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin
Description: one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
Study: NCT01734798

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study: NCT00821353

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF catheter ablation
Description: RF catheter ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drugs
Description: One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
Study: NCT01695265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercie oronasal breathing (ONB)
Description: 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercie nasal breathing through the FB
Description: Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
Study: NCT04318795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive spinal decompression (MIS-D)
Description: lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive spinal decompression and fusion (MIS-TLIF)
Description: lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
Study: NCT00877253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM 220mg/㎡, Carboplatin 5AUC
Description: Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM 260mg/㎡, Carboplatin 5AUC
Description: Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM 300mg/㎡, Carboplatin 5AUC
Description: Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
Study: NCT04691726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 10mg/ml
Description: bolus i.v. + continuous i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bolus i.v. + continuous i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole
Description: 2,5 g i.v. BD
Study: NCT01734798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy and Drug
Study: NCT02342847

Intervention type: OTHER
Intervention: N/A (non-interventional study)
Study: NCT03333928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTD1801
Description: HTD1801 tablets, 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTD1801
Description: HTD1801 tablets, 250 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets manufactured to mimic HTD1801 tablets
Study: NCT03358355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unacelyated ghrelin
Description: We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
Study: NCT00249912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Study: NCT02936362

Intervention type: OTHER
Group type: OTHER
Intervention: Consumption of sourdough bread
Description: Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)

Intervention type: OTHER
Group type: OTHER
Intervention: Consumption of sourdough bread
Description: Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
Study: NCT04691726

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metamizole
Description: 2,5 g i.v. BD
Study: NCT02936362

Intervention type: OTHER
Group type: OTHER
Intervention: Consumption of white bread
Description: Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
Study: NCT04691726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: continuous i.v. infusion adjusted to VAS scale score

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: continuous i.v. infusion adjusted to VAS scale score
Study: NCT01103830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim™
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
Study: NCT04050475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
Study: NCT03053973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nocturnal noninvasive ventilation
Description: Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.

Intervention type: DEVICE
Group type: OTHER
Intervention: nocturnal noninvasive ventilation
Description: Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
Study: NCT01596868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and cisplatin
Description: Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Description: Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
Study: NCT02687945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient physiotherapy
Study: NCT01446549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensive antigravity locomotor exercise
Description: High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
Study: NCT02396108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin + ASLAN001
Description: Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks
Study: NCT01446549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation implantation
Study: NCT02461849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400mg qd daily
Study: NCT02436915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
Study: NCT00149110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 3 days with a normal night between
Study: NCT02687945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided physiotherapy
Study: NCT00149110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Daily light therapy for 29 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diurnal rhythms
Description: Keeping the day-night cycle constant by use of educational measures

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Moderate intensity daily exercise for 30 minutes at least

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 60 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: 60 mg daily
Study: NCT01877005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT01103830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riamet®
Description: 4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo and finally Moxifloxacin
Description: 3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim™
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim™
Description: 3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo and finally Moxifloxacin
Description: 3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning.
Study: NCT04653272

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
Study: NCT03154515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04367155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: hemostatics use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: hemostatics use
Study: NCT01420224

Intervention type: OTHER
Intervention: Commercial airline flight
Description: Normal scheduled passenger flight

Intervention type: OTHER
Intervention: Commercial airline flight
Description: Normal scheduled passenger flight
Study: NCT02657694

Intervention type: DRUG
Intervention: Sofosbuvir+Ledipasvir
Description: DAA medication treatment

Intervention type: DRUG
Intervention: Sofosbuvir+Daclatasvir
Description: DAA medication treatment

Intervention type: DRUG
Intervention: Sofosbuvir+Velpatasvir
Description: DAA medication treatment
Study: NCT06464731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVT
Description: Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
Study: NCT03136224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocautery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic Clamping

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Surgical Circumcision
Study: NCT04540029

Intervention type: OTHER
Intervention: Maternal stress
Description: Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.